Scilex Holding Company (NasdaqCM: SCLX)
Health Care · Pharmaceuticals · US
$5.66
-1.22% today · -68.7% 1Y
Scilex Holding Company (NasdaqCM: SCLX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $40.31M and employs 34 people.
Over the last twelve months the share price has lost 68.7%, trading between 4.20 and 34.27.
Tweenvest scores Scilex Holding Company across four factors: quality 23/100, value 54/100, growth 90/100. Its strongest factor is growth.
SCLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $40.31M
- Revenue (TTM)
- $31.61M
- P/E
- —
- EPS
- -51.60
- Dividend yield
- —
- Beta (5Y)
- 1.74
- 52-week high
- $34.27
- 52-week low
- $4.20
- Avg volume (3M)
- —
- Shares outstanding
- 7.03M
- Employees
- 34
- Next earnings
- —
About Scilex Holding Company
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
- ISIN
- US80880W2052
- Listed since
- Mar 5, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.